Retrospective Analysis of the Safety and Efficacy of Hydroxychloroquine in Immune Thrombocytopenia (HCQITP)
Systemic Lupus Erythematosus
|Study Design:||Observational Model: Cohort
Time Perspective: Retrospective
|Official Title:||Retrospective Analysis of the Safety and Efficacy of Hydroxychloroquine in Immune Thrombocytopenia Among 40 Patients|
- Number of patients achieving a response (Platelet count > 30x10^9/L and doubling of the baseline count) or a complete response (platelet count > 100x10^9/L for a t least 6 months) [ Time Frame: one year ] [ Designated as safety issue: Yes ]Time to achieve a response, concomittant(s) treatment(s), need for an emergency treatment
- Tolerance of Hydroxychloroquine [ Time Frame: one year ] [ Designated as safety issue: Yes ]allergy, myopathy HCQ induced
|Study Start Date:||December 2010|
|Study Completion Date:||December 2011|
|Primary Completion Date:||December 2011 (Final data collection date for primary outcome measure)|
Hydroxychloroquine (HCQ) is usually used in Patients with Systemic Lupus Erythematosus (SLE) in order to treat mainly arthralgia or skin manifestations of this disease. A few studies have previously shown that HCQ could also be useful for treating autoimmune cytopenia and particularly autoimmune thrombopenia associated with SLE. In this retrospective study, the investigators have selected patients followed in our center and who have received HCQ either for an authentic SLE or because they had positive antinuclear antibodies (> 1/160e on HEP2 cells) without a definite SLE according to the American College of Rheumatology.
The main goal of this study is to compare the efficacy of HCQ in these two subgroups of patients.
No Contacts or Locations Provided